vascular stent system News
-
BioMimics 3D Vascular Stent System granted Shonin in Japan – December 2019
The BioMimics 3D Vascular Stent System received Shonin regulatory approval in Japan. On December 19th, 2019, Japanese MHLW PMDA granted Marketing Pre-Market Approval (“Shonin”) for BioMimics 3D Vascular Stent System to improve luminal diameter during endovascular intervention in patients with symptomatic peripheral arterial disease in the femoropopliteal artery. The approved ...
-
BioMimics 3D, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration
HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent ...
-
36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live. MIMICS-2 is a prospective, single-arm, multi-centre clinical study to evaluate the safety and effectiveness of the BioMimics 3D® Vascular Stent System in the treatment of patients with symptomatic atherosclerotic ...
-
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up. 01 September 2020 Nick Yeo, Veryan’s CEO ...
-
ASTM F2743 - 11 standard guide for coating inspection and acute particulate characterization of coated drug-eluting vascular stent systems
The shedding of the coating from a vascular stent can alter its clinical safety and/or therapeutic benefit. Clinical performance (for example, drug elution) may be affected by particulate generation from the coated stent system and coating defects. This document provides guidance for coating inspection and acute particulate characterization of drug eluting ...
-
Orchestra BioMed Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams. Juan Lorenzo, an expert in vascular devices, joins as vice president, product development, Focal Therapies and will ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you